U.S. District Judge Jennifer L. Hall determined that the complaint against Humana, its former CEO, and its former CFO warrants a trial. The legal action alleges that between July 2022 and October 2024, the company downplayed the financial impact of a surge in post-pandemic medical utilization. While executives maintained a positive outlook, they reportedly offloaded more than $104 million in company shares.

The facade crumbled in October 2024 when Humana disclosed significant drops in its health plan Star ratings, triggering a sharp sell-off. Law firm Schubert Jonckheer & Kolbe LLP is now expanding an investigation into potential breaches of fiduciary duty by the company’s leadership. Shareholders impacted by the share price decline are currently evaluating whether to join collective legal efforts to recover losses linked to the alleged misrepresentations.